These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25095883)

  • 1. Are we improving care of Medicare patients undergoing primary prevention implantable cardioverter-defibrillator implantation?
    Russo AM
    Circulation; 2014 Sep; 130(10):808-10. PubMed ID: 25095883
    [No Abstract]   [Full Text] [Related]  

  • 2. Temporal trends in patient characteristics and outcomes among Medicare beneficiaries undergoing primary prevention implantable cardioverter-defibrillator placement in the United States, 2006-2010. Results from the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Borne RT; Peterson PN; Greenlee R; Heidenreich PA; Wang Y; Curtis JP; Tzou WS; Varosy PD; Kremers MS; Masoudi FA
    Circulation; 2014 Sep; 130(10):845-53. PubMed ID: 25095884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR).
    Russo AM; Daugherty SL; Masoudi FA; Wang Y; Curtis J; Lampert R
    Am Heart J; 2015 Aug; 170(2):330-8. PubMed ID: 26299231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward more optimal use of primary prevention implantable cardioverter-defibrillators: how do we get there?
    Al-Khatib SM
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):140-2. PubMed ID: 21406668
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death: Prevalence and Impact on Mortality.
    Green AR; Leff B; Wang Y; Spatz ES; Masoudi FA; Peterson PN; Daugherty SL; Matlock DD
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):23-30. PubMed ID: 26715650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Implantable Cardioverter-Defibrillator Used in Heart Failure with Reduced Ejection Fraction as Primary Prevention in an Underserved Population.
    Lu Y; Wan N; Madan N; Hovnanians N; Ruiz Diaz JC; Christia P; Faillace R
    J Gen Intern Med; 2018 Nov; 33(11):1854-1856. PubMed ID: 29971636
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention implantable cardioverter defibrillators in women: More questions than answers.
    Zeitler EP; Al-Khatib SM
    Am Heart J; 2015 Aug; 170(2):197-9. PubMed ID: 26299213
    [No Abstract]   [Full Text] [Related]  

  • 11. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention implantable cardioverter-defibrillators and survival in older women.
    Zeitler EP; Hellkamp AS; Fonarow GC; Hammill SC; Curtis LH; Hernandez AF; Al-Khalidi HR; Curtis JP; Heidenreich PA; Anstrom KJ; Peterson ED; Mark DB; Hammill BG; Sanders GD; Al-Khatib SM
    JACC Heart Fail; 2015 Feb; 3(2):159-67. PubMed ID: 25543969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to the Center for Medicare & Medicaid Services coverage with evidence development request for primary prevention implantable cardioverter-defibrillators: data from the OMNI study.
    Sweeney MO; Sakaguchi S; Simons G; Machado C; Connett JE; Yang F;
    Heart Rhythm; 2012 Jul; 9(7):1058-66. PubMed ID: 22387371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry.
    Kaiser DW; Tsai V; Heidenreich PA; Goldstein MK; Wang Y; Curtis J; Turakhia MP;
    Heart Rhythm; 2015 Oct; 12(10):2086-93. PubMed ID: 25982720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients?
    Barra S; Providencia R; Agarwal S
    Int J Cardiol; 2016 Jan; 203():184-6. PubMed ID: 26512835
    [No Abstract]   [Full Text] [Related]  

  • 16. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator.
    Rho RW; Patton KK; Poole JE; Cleland JG; Shadman R; Anand I; Maggioni AP; Carson PE; Swedberg K; Levy WC
    Circulation; 2012 Nov; 126(20):2402-7. PubMed ID: 23072904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients.
    Zhang Y; Blasco-Colmenares E; Harms AC; London B; Halder I; Singh M; Dudley SC; Gutmann R; Guallar E; Hankemeier T; Tomaselli GF; Cheng A
    Europace; 2016 Sep; 18(9):1383-90. PubMed ID: 26498162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement.
    Heidenreich PA; Tsai V; Curtis J; Wang Y; Turakhia MP; Masoudi FA; Varosy PD; Goldstein MK
    Am Heart J; 2015 Aug; 170(2):281-289.e2. PubMed ID: 26299225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implant and clinical characteristics for pediatric and congenital heart patients in the national cardiovascular data registry implantable cardioverter defibrillator registry.
    Jordan CP; Freedenberg V; Wang Y; Curtis JP; Gleva MJ; Berul CI
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1092-100. PubMed ID: 25287482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction.
    Chan LL; Lim CP; Aung ST; Quetua P; Ho KL; Chong D; Teo WS; Sim D; Ching CK
    Singapore Med J; 2016 Apr; 57(4):182-7. PubMed ID: 27075476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.